BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

...That includes Philogen S.p.A., whose Phase III-stage Daromun...
BioCentury | May 13, 2019
Financial News

Philogen bypasses VCs, taps Italian syndicate for €62M to fuel late stage cancer programs

...co-founder Dario Neri told BioCentury. Both use antibody fusion constructs to deliver cytokine payloads; Daromun (L19IL2/L19TNF...
...variants of extracellular matrix components, such as fibers, which are found around tumor blood vessels. Daromun...
...ED-B domain isoform; IL-2 - Interleukin-2; TNF - Tumor necrosis factor Elizabeth S. Eaton, Staff Writer. Daromun (L19IL2/L19TNF) Fibromun...
BioCentury | Mar 2, 2018
Product Development

Clever pegylation pay off

...A) In the Phase III study, Darleukin is being given as a component of Philogen’s Daromun...
BioCentury | Feb 10, 2017
Emerging Company Profile

Improving the original immunotherapy

...an L19 Fab targeting a tumor vasculature isoform of fibronectin ( FN1 ; FN), and Daromun...
BioCentury | Dec 20, 2016
Distillery Therapeutics

Cancer

...targeting antibody L19, in Phase III for melanoma and Phase I for B cell lymphoma; daromun...
BioCentury | Oct 27, 2016
Targets & Mechanisms

Cancer’s Phoenix

...targeting a tumor vasculature isoform of fibronectin (FN1; FN) B cell lymphoma; melanoma Phase III Daromun...
Items per page:
1 - 6 of 6